NDA 20-031/S-024/S-031
NDA 20-710/S-003/S-009

15 FEB 2001

SmithKline Beecham Pharmaceuticals
Attention: Thomas Kline
Assistant Director, U.S. Regulatory Affairs
1250 S. Collegeville Road, P.O. Box 5089
Collegeville, PA 19426-0989

Dear Mr. Kline:

Please refer to your supplemental new drug applications dated September 18, 1998 (20-031/S-024 and 20-710/S-003) and October 3, 2000 (NDAs 20-031/S-031 and 20-710/S-009), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Paxil (paroxetine hydrochloride) Immediate Release Tablets (NDA 20-031) and Oral Suspension (NDA 20-710).

We additionally refer to an Agency approvable letter dated September 29, 1998 for NDAs 20-031/S-024 and 20-710/S-003, an Agency approvable letter dated November 3, 2000 for NDAs 20-031/S-031 and 20-710/S-009, and to an Agency approval letter dated May 11, 1999 for 20-031/S-023.

We acknowledge receipt of your submission dated December 15, 2000, providing for a response to our November 3, 2000, Agency letter.

These supplemental new drug applications provide for the following revisions to the prescriber labeling:

20-031/S-024 and 20-710/S-003

1. The addition to the **CONTRAINDICATIONS** section of patients with hypersensitivity to paroxetine or the paroxetine inactive ingredients.
2. Revisions to the **CLINICAL PHARMACOLOGY-Pharmacokinetics** and the **DOSAGE AND ADMINISTRATION** sections to include the results of a food interaction study.
3. A few minor editorial revisions.

20-031/S-031 and 20-710/S-009

Revisions to the **CONTRAINDICATIONS**, **WARNINGS**, and **PRECAUTIONS** sections of labeling to describe a potential interaction between paroxetine and thioridazine.

We have completed the review of supplemental applications 20-031/S-031 and 20-710/S-009 and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted December 15, 2000/Label Code LX18A), which incorporates all of the revisions listed. Accordingly, these supplemental applications are approved effective on the date of this letter.

Labeling changes of the kind which you have proposed under supplemental applications 20-031/S-031 and 20-710/S-009 are permitted by section 314.70(c) of the regulations to be instituted prior to approval of these supplements. It is understood that the changes, described in the above NDA supplements, have been made.

Additionally, we note that the revisions proposed under supplemental applications 20-031/S-024 and 20-710/S-003 were incorporated in the approval of 20-031/S-023 (Agency approval letter dated May 11, 1999), and therefore these applications are superceded by the approval of 20-031/S-023. Therefore, supplemental applications 20-031/S-024 and 20-710/S-003 will be retained in our files.

However, we remind you of your agreement to examine your worldwide safety database to further evaluate, and submit your report to the Agency, of the adverse events glaucoma and neuroleptic malignant syndrome (NMS). This report incorporating information as requested in the Agency letter dated September 29, 1998, should be submitted within 3 months of receiving this letter.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Mr. Paul David, R.Ph., Senior Regulatory Project Manager, at (301) 594-5530.

Sincerely,

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research